Validation system draws varying reactions

The majority of small- and medium-sized pharmaceutical companies have called for the government to delay the controversial validation system under the current Good Clinical Practice (cGMP) due to heavier financial burden associated with quality control testing, control system, and additional facilities and equipment, according to pharmaceutical business sources.

However, the Korea Food and D...